ArticleActa naturae2009
Modern Technologies for Creating Synthetic Antibodies for Clinical application.
Article in Acta naturae, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- An anti-idiotypic single domain antibody as Cry2Aa toxin mimotope and analysis of its binding region through molecular docking.BMC biotechnology · 2025Article
- Sensitive electrochemical gold nanoparticle-based immunosensor for norovirus detection in food samples.RSC advances · 2024Article
- Minibody-Based and scFv-Based Antibody Fragment-Drug Conjugates Selectively Eliminate GD2-Positive Tumor Cells.International journal of molecular sciences · 2023Article
- Molecularly Imprinted Ligand-Free Nanogels for Recognizing Bee Venom-Originated Phospholipase A2 Enzyme.Polymers · 2022Article
- Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors.Journal for immunotherapy of cancer · 2022Article
- Plant production of high affinity nanobodies that block SARS-CoV-2 spike protein binding with its receptor, human angiotensin converting enzyme.Frontiers in bioengineering and biotechnology · 2022Article
- Immunoglobulin A, an Active Liaison for Host-Microbiota Homeostasis.Microorganisms · 2021Review
- Recent Progress in Electrochemical Immunosensors.Biosensors · 2021Review
- Natural and Designed Toxins for Precise Therapy: Modern Approaches in Experimental Oncology.International journal of molecular sciences · 2021Review
- UCNP-based Photoluminescent Nanomedicines for Targeted Imaging and Theranostics of Cancer.Molecules (Basel, Switzerland) · 2020Article
- Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency.Cancers · 2019Review
- Development and investigation of recombinant immunotoxin protein 4D5scFv-mCherry-PE(40).Doklady. Biochemistry and biophysics · 2016Article
- Synthesis of magnetic silica nanomarkers with controlled physicochemical properties.Doklady. Biochemistry and biophysics · 2016Article
- Clinical and experimental studies of multiple sclerosis in Russia: experience of the leading national research centers.Degenerative neurological and neuromuscular disease · 2015Article
- Mechanism of the cytotoxic action of immunophototoxin 4D5scFV-miniSOG on HER2/neu-positive cancer cells.Doklady. Biochemistry and biophysics · 2015Article
- Genetically modified proteins: functional improvement and chimeragenesis.Bioengineered · 2015Review
- Specific visualization of tumor cells using upconversion nanophosphors.Acta naturae · 2014Article
- Effective Genetic Expression of Nanoantibodies by Recombinant Adenoviral Vector in vitro.Acta naturae · 2011Article
- Gold nanoparticles in biology and medicine: recent advances and prospects.Acta naturae · 2011Article
- Quantum dots for molecular diagnostics of tumors.Acta naturae · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The modular structure and versatility of antibodies enables one to modify natural immunoglobulins in different ways for various clinical applications. Rational design and molecular engineering make it possible to directionally modify the molecular size, affinity, specificity, and immunogenicity and effector functions of an antibody, as well as to combine them with other functional agents. This review focuses on up-to-date methods of antibody engineering for diagnosing and treating various diseases, particularly on new technologies meant to refine the effector functions of therapeutic antibodies.
Identifiers
22649585PMC3347500What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.